HEAL Initiative: Exploratory Data and Methods to Address Urgent Needs to Stem the Opioid Epidemic (R21- Clinical Trial Not Allowed) | RFA DA 22 045

Frequently Asked Questions (FAQs)

What is this NIH HEAL Initiative funding opportunity (RFA-DA-22-045) about?

This funding opportunity supports exploratory research to improve how existing data can be used to understand and respond to the opioid epidemic faster and more effectively. The emphasis is on developing new methods, approaches, and practical tools that make current data streams more timely, usable, and actionable for prevention and treatment decision-making.

What grant mechanism is used for this opportunity?

The opportunity uses the NIH R21 mechanism, which is typically intended for early-stage, exploratory, and potentially high-impact work rather than large-scale, long-term implementation projects.

What is the main goal of the projects funded under this FOA?

The main goal is to reduce the time lag between when opioid-related events are recorded in real-world systems (such as emergency department visits, prescription fills, or death records) and when those data become available for public health or clinical action. The FOA prioritizes methods that move surveillance and analytics toward real-time or near real-time actionable intelligence.

Does this FOA support building new large data systems from scratch?

No. The core idea is not to create new large data systems from the ground up, but to develop methods and tools that can be applied to data streams that already exist.

What kinds of data sources are considered "existing data streams" for this program?

The FOA highlights examples such as electronic health records, syndromic surveillance feeds, insurance claims, disease or treatment registries, pharmacy dispensing records, and mortality data.

What types of outcomes or insights are projects expected to produce?

Projects are expected to generate novel insights into patterns and changes in opioid and other prescription drug misuse, addiction trajectories, recovery, relapse, and related outcomes, with a strong emphasis on supporting prevention and treatment decisions.

Why is "speed and usability" emphasized in this opportunity?

The FOA prioritizes work that makes data useful quickly enough to support action. Instead of retrospective reports that arrive months later, the intent is to enable rapid analytics and decision support that can be used by public health and clinical stakeholders in near real time.

What are examples of method or tool development that fit the intent of this FOA?

Examples mentioned or implied in the FOA include rapid data linkage across systems, improved case definitions for identifying opioid-related events in messy real-world data, automated or semi-automated cleaning and harmonization routines, approaches that improve signal detection in surveillance feeds, and tools that help frontline decision-makers interpret and act on data more quickly.

What does "real-time or near real-time analytics" mean in the context of this FOA?

In this context, it refers to approaches that significantly reduce delays between event capture and analytic availability so that outputs can inform timely public health or clinical decisions, rather than being limited to delayed, retrospective summaries.

What does the FOA mean by improving usability for local or substate jurisdictions?

The FOA emphasizes making data more timely and granular for counties, cities, and regions that often struggle to obtain reliable local-level information. The goal is to help local decision-makers identify emerging hotspots, shifting patterns, and intervention effects that may be hidden by state-level averages.

What is small area estimation, and why is it highlighted?

Small area estimation refers to statistical or computational methods that generate reliable local estimates even when local data are sparse, delayed, or noisy. The FOA highlights this because many opioid response decisions are made at the county, city, or regional level, where direct data can be limited or slow to arrive.

How could small area estimation support opioid response efforts?

Methods that produce reliable local estimates can help identify localized spikes in risk, detect emerging hotspots sooner, allocate resources more intelligently, and track the effects of interventions in a timely way.

Are clinical trials allowed under this funding opportunity?

No. The FOA specifies "Clinical Trial Not Allowed," meaning applicants should not propose research in which participants are prospectively assigned to an intervention to evaluate health-related outcomes.

What kind of research is appropriate given the "Clinical Trial Not Allowed" restriction?

The opportunity is focused on methods development and analytics using existing data sources. The FOA indicates this could include retrospective analyses, algorithm development, validation studies using historical data, and creation of tools or workflows that improve surveillance and decision support without conducting an interventional clinical trial.

Who is eligible to apply?

Eligibility is broad and includes many U.S.-based organizations and government entities. Examples include state, county, city or township governments; special district governments; independent school districts; public housing authorities/Indian housing authorities; public and private institutions of higher education; nonprofit organizations with or without 501(c)(3) status (other than institutions of higher education); for-profit organizations other than small businesses; small businesses; federally recognized Native American tribal governments; and Native American tribal organizations that are not federally recognized tribal governments.

Are specific institution types explicitly highlighted as eligible?

Yes. The FOA highlights additional eligible applicant types including Alaska Native and Native Hawaiian Serving Institutions, Asian American Native American Pacific Islander Serving Institutions (AANAPISIs), Hispanic-serving institutions, Historically Black Colleges and Universities (HBCUs), Tribally Controlled Colleges and Universities (TCCUs), eligible federal agencies, faith-based or community-based organizations, regional organizations, and U.S. territories or possessions.

Are foreign organizations or non-U.S. entities eligible to apply?

No. The FOA states that non-U.S. entities (foreign organizations and foreign institutions) are not eligible to apply.

Are non-domestic components of U.S. organizations allowed?

No. The FOA states that non-domestic components of U.S. organizations are not eligible.

Are foreign components allowed under NIH policy for this FOA?

No. The FOA specifies that foreign components (as defined by NIH policy) are not allowed.

What is the program trying to improve about opioid-related surveillance and data use?

The program is designed to improve the timeliness, efficiency, and local usefulness of opioid-related surveillance and health data so that prevention and treatment responses can be faster and better targeted.

What administrative category is this opportunity listed under?

It is categorized as a discretionary NIH grant under activity areas spanning education and health.

Which CFDA numbers are referenced in the opportunity?

The FOA references CFDA numbers 93.121, 93.213, 93.279, 93.846, and 93.866.

When was the FOA created, and what closing date is listed?

The FOA was created on December 20, 2021, and the original closing date listed is March 10, 2022.

Does the provided information include an award ceiling or the expected number of awards?

No. The source excerpt does not provide an award ceiling or the expected number of awards.

What does the R21 structure suggest about the type of projects NIH is trying to fund here?

Based on the R21 mechanism and the described priorities, the program is intended to seed innovative, methodologically focused projects that can quickly improve how existing opioid-related data are turned into timely, actionable intelligence.